NPPA outcome data 2022/23
This is a list of decisions on NPPA applications with their outcomes. We've included the indication where it would not compromise anyone's privacy.
Download the data as a spreadsheet (includes medicines, outcomes and some indications)
- NPPA Data 2022 23 Includes indications [XLSX 29 KB]
Call the team if you have any questions about your particular medicine.
Outcomes of applications by medicine 2022/23
( | Collapse/Expand All) |
Medicine | Approved | Declined | Principles not met | Withdrawn application | Total | ||
---|---|---|---|---|---|---|---|
adalimumab | 11 | 2 | 13 | ||||
Indication | |||||||
chronic recurrent multifocal osteomyelitis | 4 | 4 | |||||
Other indication(s) | 7 | 2 | 9 | ||||
alpha tocopheryl acetate | 49 | 1 | 50 | ||||
Indication | |||||||
cystic fibrosis (CF) | 4 | 4 | |||||
liver disease or short gut syndrome | 36 | 36 | |||||
liver disease or short gut syndrome, Biliary Atresia | 1 | 1 | |||||
Liver disease, EBV infection, Oral liquid required (child) | 1 | 1 | |||||
other indication(s) | 7 | 1 | 8 | ||||
anakinra | 9 | 1 | 10 | ||||
Indication | |||||||
other indication(s) | 9 | 1 | 10 | ||||
asparaginase | 7 | 7 | |||||
Indication | |||||||
ALL | 4 | 4 | |||||
other indication(s) | 3 | 3 | |||||
atezolizumab | 6 | 1 | 7 | ||||
Indication | |||||||
Other indication(s) | 6 | 1 | 7 | ||||
azacitidine | 5 | 5 | |||||
Indication | |||||||
Other indication(s) | 5 | 5 | |||||
azithromycin | 1 | 1 | 2 | 4 | |||
Indication | |||||||
Other indication(s) | 1 | 1 | 2 | 4 | |||
bedaquiline | 11 | 11 | |||||
Indication | |||||||
Multi-drug resistant (MDR) tuberculosis (TB) | 5 | 5 | |||||
Other indication(s) | 6 | 6 | |||||
bevacizumab | 9 | 6 | 15 | ||||
Indication | |||||||
Other indication(s) | 9 | 6 | 15 | ||||
biotin | 6 | 6 | |||||
Indication | |||||||
Other indication(s) | 6 | 6 | |||||
blinatumomab | 7 | 1 | 8 | ||||
Indication | |||||||
B-ALL | 4 | 1 | 5 | ||||
Other indication(s) | 3 | 3 | |||||
brentuximab vedotin | 17 | 1 | 18 | ||||
Indication | |||||||
Other indication(s) | 4 | 4 | |||||
relapsed/refractory CD30-positive Hodgkin lymphona | 13 | 1 | 14 | ||||
canakinumab | 4 | 4 | |||||
Indication | |||||||
Other indication(s) | 4 | 4 | |||||
cannabinoid | 3 | 10 | 1 | 14 | |||
Indication | |||||||
Epilepsy | 3 | 1 | 4 | ||||
Other indication(s) | 3 | 7 | 10 | ||||
ciclosporin eye preparations | 85 | 1 | 1 | 87 | |||
Indication | |||||||
allergic conjunctivitis | 2 | 2 | |||||
allergic conjunctivitis, keratoconjunctivitis sicca | 1 | 1 | |||||
allergic eye disease | 2 | 2 | |||||
allergic eye disease, limbitis, reactive fibrovascular growth to temporal conjunctiva | 1 | 1 | |||||
allergic eye disease, Sjogren's syndrome | 1 | 1 | |||||
allergic keratoconjunctivitis | 1 | 1 | |||||
allergic keratoconjunctivitis, giant papillarly conjunctivitis | 1 | 1 | |||||
atopic conjunctivitis | 1 | 1 | |||||
atopic conjunctivitis, allergic conjunctivitis | 2 | 2 | |||||
atopic keratoconjunctivitis | 4 | 1 | 5 | ||||
atopic keratoconjunctivitis, limbitis | 1 | 1 | |||||
bilateral keratoconus, corneal graft, giant papillarly conjunctivitis | 1 | 1 | |||||
Bilateral Superior Conjunctival Epithelium Growth | 1 | 1 | |||||
Blepharitis, ocular rosacea, meibomian gland dysfunction | 1 | 1 | |||||
blepharokeratoconjunctivitis | 2 | 2 | |||||
corneal neovascularisation | 1 | 1 | |||||
dry eyes | 1 | 1 | |||||
dry eyes, ocular surface inflammation | 1 | 1 | |||||
dry eyes, ocular surface inflammation, NOT RARE DISORDER - REPORTING PURPOSES ONLY | 1 | 1 | |||||
Graft vs Host Disease | 1 | 1 | |||||
Inferior punctuate erosions | 1 | 1 | |||||
keratoconjunctivitis sicca | 5 | 5 | |||||
keratoconjunctivitis sicca, allergic conjunctivitis | 1 | 1 | |||||
keratoconjunctivitis sicca, dry eyes | 1 | 1 | |||||
keratoconjunctivitis sicca, severe dry eye | 2 | 2 | |||||
keratoconjunctivitis sicca, severe dry eyes | 2 | 2 | |||||
keratoconjunctivitis sicca, Sjogren's syndrome | 2 | 2 | |||||
marginal keratitis, Blepharitis, meibomian gland dysfunction | 1 | 1 | |||||
meibomian gland dysfunction | 1 | 1 | |||||
neuropathic keratopathy, corneal scarring | 1 | 1 | |||||
ocular graft vs host disease | 1 | 1 | |||||
ocular inflammation | 1 | 1 | |||||
other indication(s) | 1 | 1 | |||||
rosacea keratitis | 1 | 1 | |||||
severe allergic conjunctivitis | 2 | 2 | |||||
severe dry eye | 1 | 1 | |||||
severe dry eye, NOT RARE DISORDER - REPORTING PURPOSES ONLY | 1 | 1 | |||||
severe dry eyes, Sjogren's syndrome | 1 | 1 | |||||
severe keratoconjunctivitis sicca | 3 | 3 | |||||
Severe ocular rosacea | 1 | 1 | |||||
severe secretory dry eye | 4 | 4 | |||||
severe secretory dry eye, connective tissue disorder, Sjogren's syndrome | 1 | 1 | |||||
severe secretory dry eye, NOT RARE DISORDER - REPORTING PURPOSES ONLY | 1 | 1 | |||||
severe secretory dry eye, rheumatoid arthritis, Sjogren's syndrome | 1 | 1 | |||||
severe secretory dry eye, RhF positive | 1 | 1 | |||||
vernal blepharoconjunctivitis | 1 | 1 | |||||
vernal conjunctivitis, keratitis, veratoconus | 1 | 1 | |||||
vernal keratoconjunctivitis (VKC) | 19 | 19 | |||||
cinacalcet | 2 | 2 | 4 | ||||
Indication | |||||||
other indication(s) | 2 | 2 | 4 | ||||
continuous glucose monitoring system | 8 | 6 | 2 | 16 | |||
Indication | |||||||
Other indication(s) | 7 | 1 | 2 | 10 | |||
type 1 diabetes | 1 | 5 | 6 | ||||
dabrafenib | 5 | 1 | 6 | ||||
Indication | |||||||
other indication(s) | 5 | 1 | 6 | ||||
dasatinib | 3 | 1 | 4 | ||||
Indication | |||||||
Other indication(s) | 3 | 1 | 4 | ||||
deferasirox | 4 | 2 | 1 | 7 | |||
Indication | |||||||
iron overload | 3 | 1 | 4 | ||||
Other indication(s) | 1 | 1 | 1 | 4 | |||
denosumab | 5 | 5 | 10 | ||||
Indication | |||||||
Giant cell tumour of the bone | 4 | 1 | 5 | ||||
Other indication(s) | 1 | 4 | 5 | ||||
dupilumab | 3 | 1 | 4 | ||||
Indication | |||||||
Other indication(s) | 3 | 1 | 4 | ||||
eculizumab | 2 | 1 | 1 | 1 | 5 | ||
Indication | |||||||
Other indication(s) | 2 | 1 | 1 | 1 | 5 | ||
eltrombopag | 3 | 1 | 4 | ||||
Indication | |||||||
Other indication(s) | 3 | 1 | 4 | ||||
enoxaparin sodium | 4 | 2 | 6 | ||||
Indication | |||||||
Other indication(s) | 4 | 2 | 6 | ||||
etanercept | 2 | 1 | 1 | 4 | |||
Indication | |||||||
Other indication(s) | 2 | 1 | 1 | 4 | |||
fenfluramine | 3 | 1 | 4 | ||||
Indication | |||||||
dravet's syndrome | 3 | 1 | 4 | ||||
galcanezumab | 1 | 3 | 4 | ||||
Indication | |||||||
chronic migraine | 1 | 3 | 4 | ||||
ganciclovir eye preparations | 4 | 4 | |||||
Indication | |||||||
Cytomegalovirus (CMV) uveitis | 4 | 4 | |||||
ibrutinib | 1 | 6 | 7 | ||||
Indication | |||||||
other indication(s) | 1 | 6 | 7 | ||||
imiglucerase | 5 | 5 | |||||
Indication | |||||||
Gaucher's Disease | 5 | 5 | |||||
indomethacin | 4 | 4 | |||||
Indication | |||||||
other indication(s) | 4 | 4 | |||||
infliximab | 7 | 4 | 11 | ||||
Indication | |||||||
Other indication(s) | 7 | 4 | 11 | ||||
inotuzumab ozogamicin | 4 | 4 | |||||
Indication | |||||||
Other indication(s) | 4 | 4 | |||||
insulin pump consumables | 3 | 4 | 7 | ||||
Indication | |||||||
other indication(s) | 1 | 2 | 3 | ||||
Type 1 diabetes | 2 | 2 | 4 | ||||
ivabradine | 1 | 4 | 1 | 6 | |||
Indication | |||||||
atrial tachycardias | 1 | 1 | |||||
inappropriate sinus tachycardia | 4 | 1 | 5 | ||||
ketamine | 8 | 8 | |||||
Indication | |||||||
pallative care pain | 8 | 8 | |||||
lamotrigine | 10 | 5 | 1 | 16 | |||
Indication | |||||||
Epilepsy | 10 | 3 | 1 | 14 | |||
Other indication(s) | 2 | 2 | |||||
lenalidomide | 6 | 1 | 7 | ||||
Indication | |||||||
myelodysplastic syndrome with 5q deletion | 4 | 4 | |||||
Other indication(s) | 2 | 1 | 3 | ||||
levetiracetam | 31 | 1 | 32 | ||||
Indication | |||||||
palliative care, Seizures | 31 | 1 | 32 | ||||
levocarnitine | 2 | 1 | 3 | ||||
Indication | |||||||
other indication(s) | 2 | 1 | 3 | ||||
linezolid | 7 | 1 | 8 | ||||
Indication | |||||||
Multi-drug resistant (MDR) tuberculosis (TB) | 6 | 6 | |||||
Other indication(s) | 1 | 1 | 2 | ||||
liraglutide | 6 | 6 | |||||
Indication | |||||||
Obesity, high BMI | 6 | 6 | |||||
macitentan | 7 | 3 | 1 | 11 | |||
Indication | |||||||
other indication(s) | 2 | 2 | |||||
Pulmonary hypertension (PAH) | 5 | 3 | 1 | 9 | |||
melatonin | 4 | 4 | |||||
Indication | |||||||
other indication(s) | 4 | 4 | |||||
mepolizumab | 2 | 2 | 4 | ||||
Indication | |||||||
other indication(s) | 2 | 2 | 4 | ||||
mitotane | 10 | 10 | |||||
Indication | |||||||
adrenocortical carcinoma | 10 | 10 | |||||
moxifloxacin | 4 | 1 | 1 | 6 | |||
Indication | |||||||
other indication(s) | 4 | 1 | 1 | 6 | |||
nelarabine | 4 | 1 | 5 | ||||
Indication | |||||||
Acute Lymphocytic leukaemia | 4 | 1 | 5 | ||||
nirmatrelvir with ritonavir | 1 | 2 | 5 | 8 | |||
Indication | |||||||
COVID-19 | 1 | 2 | 5 | 8 | |||
octreotide lar | 4 | 1 | 5 | ||||
Indication | |||||||
Other indication(s) | 4 | 1 | 5 | ||||
olaparib | 12 | 1 | 13 | ||||
Indication | |||||||
BRCA2 mutation, metastatic breast cancer | 5 | 5 | |||||
Other indication(s) | 7 | 1 | 8 | ||||
omalizumab | 2 | 1 | 1 | 4 | |||
Indication | |||||||
Other indication(s) | 2 | 1 | 1 | 4 | |||
pazopanib | 3 | 2 | 5 | ||||
Indication | |||||||
Other indication(s) | 3 | 2 | 5 | ||||
pembrolizimab | 9 | 11 | 1 | 21 | |||
Indication | |||||||
other indication(s) | 2 | 11 | 1 | 14 | |||
placental trophoblastic tumour | 1 | 1 | |||||
relapsed Hodgkin's lymphoma | 6 | 6 | |||||
pirfenidone | 1 | 3 | 4 | ||||
Indication | |||||||
other indication(s) | 1 | 3 | 4 | ||||
posaconazole | 9 | 1 | 10 | ||||
Indication | |||||||
Other indication(s) | 9 | 1 | 10 | ||||
pristinamycin | 7 | 7 | |||||
Indication | |||||||
Mycoplasma genitalium infection | 6 | 6 | |||||
Other indication(s) | 1 | 1 | |||||
prucalopride | 6 | 6 | 1 | 13 | |||
Indication | |||||||
chronic constipation | 5 | 5 | |||||
severe gastroparesis | 6 | 1 | 1 | 8 | |||
retinol (vitamin a) | 55 | 55 | |||||
Indication | |||||||
liver disease or short gut syndrome | 46 | 46 | |||||
other indication(s) | 9 | 9 | |||||
rituximab | 26 | 5 | 3 | 34 | |||
Indication | |||||||
Other indication(s) | 26 | 5 | 3 | 34 | |||
rufinamide | 7 | 1 | 8 | ||||
Indication | |||||||
Other indication(s) | 1 | 1 | |||||
refractory epilepsy | 6 | 1 | 7 | ||||
ruxolitinib | 4 | 2 | 6 | ||||
Indication | |||||||
Graft versus host disease | 3 | 2 | 5 | ||||
Other indication(s) | 1 | 1 | |||||
sargramostim | 4 | 4 | |||||
Indication | |||||||
High risk neuroblastom | 4 | 4 | |||||
secukinumab | 7 | 3 | 10 | ||||
Indication | |||||||
Other indication(s) | 7 | 3 | 10 | ||||
sirolimus | 4 | 4 | |||||
Indication | |||||||
Other indication(s) | 4 | 4 | |||||
sunitinib | 2 | 1 | 1 | 4 | |||
Indication | |||||||
Other indication(s) | 2 | 1 | 1 | 4 | |||
tacrolimus ointment | 1 | 4 | 5 | ||||
Indication | |||||||
other indication(s) | 1 | 4 | 5 | ||||
tadalafil | 3 | 3 | 1 | 7 | |||
Indication | |||||||
Other indication(s) | 1 | 1 | |||||
Pulmonary arterial hypertension (PAH) | 2 | 3 | 1 | 6 | |||
temozolomide | 10 | 3 | 13 | ||||
Indication | |||||||
Highr risk neuroblastoma | 4 | 4 | |||||
other indication(s) | 6 | 3 | 9 | ||||
thalidomide | 4 | 1 | 5 | ||||
Indication | |||||||
other indication(s) | 4 | 1 | 5 | ||||
tocilizumab | 7 | 9 | 1 | 17 | |||
Indication | |||||||
Giant cell arteritis | 1 | 4 | 5 | ||||
Other indication(s) | 6 | 5 | 1 | 12 | |||
topotecan | 5 | 5 | |||||
Indication | |||||||
High risk neuroblastoma | 5 | 5 | |||||
trametinib | 16 | 1 | 1 | 18 | |||
Indication | |||||||
neurofibromatosis type 1 | 4 | 1 | 5 | ||||
Other indication(s) | 12 | 1 | 13 | ||||
upadacitinib | 12 | 5 | 1 | 18 | |||
Indication | |||||||
Other indication(s) | 3 | 3 | 1 | 7 | |||
severe atopic dermatitis | 9 | 2 | 11 | ||||
ustekinumab | 1 | 3 | 4 | ||||
Indication | |||||||
Other indication(s) | 1 | 3 | 4 | ||||
valganciclovir | 4 | 4 | |||||
Indication | |||||||
Cytomegalovirus (CMV) | 4 | 4 | |||||
varicella zoster virus | 5 | 1 | 6 | ||||
Indication | |||||||
shingles prevention | 5 | 1 | 6 | ||||
venetoclax | 5 | 5 | 1 | 11 | |||
Indication | |||||||
Acute myeloid leukaemia (AML) | 3 | 1 | 4 | ||||
Other indication(s) | 2 | 5 | 7 | ||||
voriconazole | 7 | 1 | 8 | ||||
Indication | |||||||
chronic aspergillosis | 4 | 4 | |||||
Other indication(s) | 3 | 1 | 4 | ||||
zonisamide | 8 | 1 | 9 | ||||
Indication | |||||||
refractory epilepsy | 8 | 1 | 9 | ||||